Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance

Zhou, Ling; Lu, Guoyuan; Shen, Lei; Wang, Linfeng; Wang, Mingjun

doi:10.1155/2014/627126

Cited by 23 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overexpression of FGF2 has also been shown to be beneficial in the experimental autoimmune encephalomyelitis model of MS [51]. In lupus, FGF2 is positively correlated with disease activity [52]. A recent study compared the protein levels of various growth factors in the cerebrospinal fluid (CSF) of lupus patients relative to subjects with disrupted BBB, such as MS. FGF2 was one of six upregulated genes that predicted lupus using a weighted algorithm [53].…”

Section: Fgf System In Neurological Disordersmentioning

confidence: 99%

Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders

Turner

Eren-Koçak

Inui³

et al. 2016

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

The role of the fibroblast growth factor (FGF) system in brain-related disorders has received considerable attention in recent years. To understand the role of this system in neurological and psychiatric disorders, it is important to identify the specific members of the FGF family that are implicated, their location and the various mechanisms they can be modulated. Each disorder appears to impact specific molecular players in unique anatomical locations, and all of these could conceivably become targets for treatment. In the last several years, the issue of how to target this system directly has become an area of increasing interest. To date, the most promising therapeutics are small molecule inhibitors and antibodies that modulate FGF receptor (FGFR) function. Beyond attempting to modify the primary players affected by a given brain disorder, it may prove useful to target molecules, such as membrane-bound or extracellular proteins that interact with FGF ligands or FGFRs to modulate signaling.

show abstract

Section: Fgf System In Neurological Disordersmentioning

confidence: 99%

Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders

Turner

Eren-Koçak

Inui³

et al. 2016

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

show abstract

“…VEGF is also required for glomerular hypertrophy and proliferation in response to nephron reduction. Loss of VEGF is associated with glomerulosclerosis and tubulointerstitial fibrosis in the remnant kidney (14). These findings suggest that serum VEGF maybe a useful diagnostic marker of active lupus nephritis.…”

Section: Discussionmentioning

confidence: 75%

“…This supports the idea that serum VEGF level may be a useful marker of disease activity and internal organ involvement in disease pathology. A more recent study observed that serum VEGF negatively correlates with plasma albumin, which suggests that disease activity may result in deterioration of nutritional conditions leading to an increase in serum VEGF levels (14). VEGF is also required for glomerular hypertrophy and proliferation in response to nephron reduction.…”

Section: Discussionmentioning

confidence: 99%

Serum Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Disease Activity in Lupus Nephritis

Ghazali

Iberahim

Ashari

2017

MJMS

View full text Add to dashboard Cite

Background: Previous studies have shown that serum VEGF levels were elevated in patients with active systemic lupus erythematosus (SLE), especially in those with lupus nephritis (LN). In this case control study, we aimed to compare serum levels of VEGF in SLE patients between LN, non-LN and healthy participants to determine the association between serum VEGF levels and the activity and histological classes of lupus nephritis.Methods: Blood samples were obtained from 92 SLE patients (46 LN and 46 non-LN) and 26 controls. Data were collected from medical records. Serum VEGF assays were performed by specific, enzyme-linked immunosorbent assay kits (ELISA). Laboratory investigations included urinalysis, urine protein-creatinine ratio, serum creatinine, albumin and VEGF levels. Blood pressure, renal biopsy result and treatment were recorded. LN activity was evaluated using the renal subscale of the British Isles Lupus Assessment Group (rBILAG, 2004). The rBILAG measures blood pressure (diastolic and systolic), urine protein, serum creatinine, calculated glomerular filtration rate (GFR), presence of active urinary sediments and histological evidence of active nephritis.Results: Serum VEGF was elevated in SLE patients with LN compared with the non-LN group and healthy controls. The levels found were significantly higher in the sera of patients with active nephritis compared to those with quiescent nephritis (P = 0.024). The study did not find a statistically significant relationship between serum VEGF levels and histological classes of LN.Conclusion: There was no significant difference of serum VEGF level between LN and non-LN SLE groups and between the non-LN group and healthy controls. However, there were increased levels of serum VEGF in the LN group, especially in patients with active nephritis as compared to quiescent nephritis group. This reflects the role of VEGF in the pathogenesis of lupus nephritis, however the clinical potential of this biomarker needs further study.

show abstract

“…FGF-basic is a potent angiogenic factor whose activity is involved in endothelial cell and fibroblast survival, proliferation, migration, and tube formation, together with VEGF [35]. An increased FGF-basic level was reported in lupus and tended to be correlated with disease activity [36].…”

Section: Discussionmentioning

confidence: 99%

Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases

Ichinose

Arima

Ushigusa

et al. 2015

Clinical Immunology

View full text Add to dashboard Cite

Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE. Although the mechanism of NPSLE remains unclear, cytokines and chemokines are considered to be involved in their pathogenesis. Here we used Bio-Plex Pro assays to examine 27 types of cytokines and chemokines in the cerebrospinal fluid (CSF) of 32 NPSLE patients. We used the CSF of 20 patients with multiple sclerosis (MS) and 22 patients with neuromyelitis optica (NMO) as a disease control group. Fourteen of 27 cytokines/chemokines were significantly higher in the NPSLE patients compared to the MS/NMO patients. We could identify six "minimum predictive markers" by using a weighted-voting algorithm that could distinguish NPSLE from MS and NMO: interleukin (IL)-17, IL-2, interferon (IFN)-γ, IL-5, basic fibroblast growth factor (FGF)-basic and IL-15. The determination of various types of CSF cytokine profiles may contribute to the diagnosis of NPSLE and may help elucidate the mechanisms underlying this disease.

show abstract

Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance

Cited by 23 publications

References 19 publications

Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders

Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders

Serum Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Disease Activity in Lupus Nephritis

Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases

Contact Info

Product

Resources

About